PHAT vs. ORIC, STOK, AVBP, CDMO, SLN, SVRA, ZYME, HROW, OLMA, and LYEL
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include ORIC Pharmaceuticals (ORIC), Stoke Therapeutics (STOK), ArriVent BioPharma (AVBP), Avid Bioservices (CDMO), Silence Therapeutics (SLN), Savara (SVRA), Zymeworks (ZYME), Harrow (HROW), Olema Pharmaceuticals (OLMA), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Phathom Pharmaceuticals received 23 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 67.65% of users gave Phathom Pharmaceuticals an outperform vote while only 65.71% of users gave ORIC Pharmaceuticals an outperform vote.
In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 7 mentions for Phathom Pharmaceuticals and 5 mentions for ORIC Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.08 beat ORIC Pharmaceuticals' score of 0.55 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media.
ORIC Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
ORIC Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 118.34%. Phathom Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 108.73%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ORIC Pharmaceuticals is more favorable than Phathom Pharmaceuticals.
ORIC Pharmaceuticals' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ORIC Pharmaceuticals has higher earnings, but lower revenue than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ORIC Pharmaceuticals and Phathom Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
